Platform

An Industry-Leading Drug Discovery Platform

RNA plays a vital role in biology and represents an untapped opportunity for therapeutic intervention. At Ribometrix, we believe the time is right to unlock this potential and have built a unique drug discovery engine to deliver small-molecule therapies that prevent the production of disease-driving proteins.

Ribometrix scientist

The Opportunity:
Applying the Power of Small Molecules
to Target RNAs

Many modern therapeutic strategies aim to address unmet medical needs by diversifying beyond the limited applicability of conventional protein targeting. Among emerging alternatives, the targeting of RNAs to correct the levels of encoded proteins is widely recognized as offering huge potential, but its applicability to date has remained severely restricted by the inherent limitations of oligonucleotide-based modalities.

The ideal solution of applying the tried-and-true power of small molecule drugs towards RNA targeting is precisely what Ribometrix has been pursuing for years. Building on groundbreaking advances in understanding the complex folding of cellular RNAs, we identify the most druggable “hot spots” within those folded structures, to then discover and develop potent small molecules that deliver their full therapeutic potential.

Ribometrix lab

A Platform to Unlock
The Full Potential of RNA Targeting

Built on nearly a decade of proprietary advances stemming from our company’s founding expertise in RNA structure analyses, our proprietary platform combines the well-established power of small molecule drug discovery and development with best-in-field RNA-focused capabilities to realize the full potential of RNA targeting.

These capabilities have driven 3 main areas of platform enablement:
1. Rational Target Prioritization (The “RTP” Approach)
2. Discovery and development of inherently functional RNA binders (RNA Modulation through Binding-Alone)
3. Engineering function into strongly selective but “silent” binders (BOLSTR™: Bioactivity Optimization of Ligands Silently Targeting RNAs)

Rational Target Prioritization

Establishing a new therapeutic modality doesn’t happen overnight. There are no silver bullets here: every new modality has its own specific strengths and limitations, all of which must be thoroughly explored and understood to identify its most effective “applicability space”.

Through years of careful and rigorous experimentation, Ribometrix has accumulated unique insights and proprietary capabilities to identify which RNA structures are most readily druggable. Such targeting “hot spots” can host highly potent and selective small molecule interactions capable of modulating the function of such RNAs in the production of encoded proteins. This crucial knowledge assures that ongoing Ribometrix efforts are focused on those therapeutic opportunities that offer the best chance of success.

RNA Modulation Through Binding Alone

Until recently, it was impossible to systematically target RNAs with small molecules due to the lack of reliable methods to consistently identify three-dimensional RNA structures or screen and optimize RNA-targeting small molecules. Ribometrix has built an industry-leading technology platform that leverages proprietary capabilities to identify and drug complex RNA structures in therapeutically compelling RNAs.

Our platform has revealed that many of these RNAs adopt unique three-dimensional structures. We validate and screen these RNA structures against diverse chemical libraries to identify druglike small molecules that bind specifically to our RNA targets. We then develop these RNA-binding small molecules into therapeutics that, through binding to mRNAs, prevent disease-causing proteins from being produced.

Engineered Function: RNA Degraders

Drug-like small molecules that show strong, selective binding to a target RNA without affecting its function will be engineered to do so in one of two ways, using our BOLSTR™ technology (Bioactivity Optimization of Ligands Silently Targeting RNAs).

The first approach uses a “monovalent degrader” strategy to add a functional group to the target-binding molecule that signals the cell to destroy the bound target RNA.

The second approach uses a “bivalent degrader” strategy to add a ligand that specifically recruits a cellular nuclease to degrade the bound target RNA, analogous to PROTACS and protein degradation.

“Through extraordinary commitment and scientific rigor, Ribometrix is now on the verge of opening a new horizon in drug discovery — RNA modulation by small molecules.”
Mike Clayman, Chairman of the Board
Ribometrix

Ribometrix’s Capabilities

We are constantly evolving our platform by incorporating state-of-the-art capabilities

RNA Platform

Industry-leading RNA capabilities are the foundation for the discovery and development of RNA-targeting small molecules across a wide range of therapeutic areas.

Experienced Team

Deep experience in RNA innovation and drug discovery, with a drive to deliver novel therapies to patients.
Ribometrix scientist
Partnership

Let’s Discover the Future Together

We are committed to building the industry’s leading RNA structure-based drug discovery capabilities, leveraging industry collaborations, using capital efficiently, and applying our passion for science to help people.

Questions about our research, platform, or opportunities? Let’s connect.